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Abstract
Background: Bone morphogenic proteins (BMPs) play a key role in bone formation. Consequently, it was expected
that topical application of recombinant human (rh)BMP-2 and rhBMP-7 would improve the healing of complex
fractures. However, up to 36% of fracture patients do not respond to this therapy. There are hints that a systemic
increase in transforming growth factor b1 (TGFb1) interferes with beneficial BMP effects. Therefore, in the present
work we investigated the influence of rhTGFb1 on rhBMP signaling in primary human osteoblasts, with the aim of
more specifically delineating the underlying regulatory mechanisms.
Methods: BMP signaling was detected by adenoviral Smad-binding-element-reporter assays. Gene expression was
determined by reverse transcription polymerase chain reaction (RT-PCR) and confirmed at the protein level by
western blot. Histone deacetylase (HDAC) activity was determined using a test kit. Data sets were compared by
one-way analysis of variance.
Results: Our findings showed that Smad1/5/8-mediated rhBMP-2 and rhBMP-7 signaling is completely blocked by
rhTGFb1. We then investigated expression levels of genes involved in BMP signaling and regulation (for example,
Smad1/5/8, TGFb receptors type I and II, noggin, sclerostin, BMP and activin receptor membrane bound inhibitor
(BAMBI), v-ski sarcoma viral oncogene homolog (Ski), Ski-related novel protein N (SnoN) and Smad ubiquitination
regulatory factors (Smurfs)) and confirmed the expression of regulated genes at the protein level. Smad7 and SnoN
were significantly induced by rhTGFb1 treatment while expression of Smad1, Smad6, TGFbRII and activin receptor-
like kinase 1 (Alk1) was reduced. Elevated SnoN expression was accompanied by increased HDAC activity. Addition
of an HDAC inhibitor, namely valproic acid, fully abolished the inhibitory effect of rhTGFb1 on rhBMP-2 and rhBMP-
7 signaling.
Conclusions: rhTGFb1 effectively blocks rhBMP signaling in osteoblasts. As possible mechanism, we postulate an
induction of SnoN that increases HDAC activity and thereby reduces the expression of factors required for efficient
BMP signaling. Thus, inhibition of HDAC activity may support bone healing during rhBMP therapy in patients with
elevated TGFb serum levels.
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Background
In order to maintain a constant bone mass in the adult
skeleton, bone remodeling underlies a coordinated pro-
cess of bone formation and bone resorption. While bone
is formed by osteoblasts, which are of mesenchymal ori-
gin, it is resorbed by osteoclasts that are derived from the
hematopoietic system. An imbalance in this process may
cause pathological loss of bone mass as seen with delayed
fracture healing, osteoporosis and other metabolic bone
diseases.
Bone morphogenic proteins (BMPs) promote osteogen-
esis, chondrogenesis and adipogenesis of mesenchymal
progenitor cells [1]. The biological activity of recombinant
human (rh)BMPs (2, 4 and 7) has been defined by using a
variety of animal models. For example, when implanted
with a suitable matrix, these rhBMPs have been shown to
enhance allograft incorporation and induce new bone for-
mation at various skeletal sites. Clinical trials using
rhBMPs were successful in the treatment of open tibial
fractures, distal tibial fractures, tibial non-unions, scaphoid
non-unions and atrophic long bone non-unions [2-7].
Despite these proven positive effects of BMPs on bone
healing, the universal use of rhBMPs is tempered by high
costs, lingering safety concerns (for example, vertebral
osteolysis, ectopic bone formation, radiculitis or cervical
soft tissue swelling), and a relatively high failure rate with
up to 36% of patients not responding to this therapy [8,9].
There are hints that a systemic increase in transforming
growth factor b (TGFb) is at least partially responsible for
this therapy resistance, as it causes BMP signaling interfer-
ence [10]. Therefore, in order to design an improved sec-
ond-generation therapy, it is necessary to fully understand
the molecular mechanisms of the activity of rhBMPs in
the setting of bone defect therapy.
TGFb, with its three isoforms (b1, b2 and b3), is by far
the most abundant cytokine in bone. All three isoforms
are secreted in their latent form within bone matrix, wait-
ing to be activated by osteoclasts during bone turnover in
order to recruit osteoblast progenitor cells, and thereby
stimulating bone formation [11]. BMPs belong to the
TGFb superfamily, where all members transduce their sig-
nals through two types of serine/threonine kinase recep-
tors, termed type I and type II [12]. The type II receptors
are constitutively active kinases that phosphorylate type I
receptors upon ligand binding. Seven type I receptors,
termed activin receptor-like kinase (Alk)1 to Alk7, have
been identified in mammals. BMPs, activins and TGFb1-3
bind different type I receptors. This binding is cell type
dependent: BMPs preferably bind Alk1, Alk2, Alk3 and
Alk6, whereas activins and TGFb1-3 bind Alk4 and Alk5,
respectively. Upon activation by the type II receptor, Alks
activate (phosphorylate) Smad transcription factors in the
cytoplasm. To date, eight different Smads have been
identified in mammals that are classified into three groups:
receptor-regulated Smads (R-Smads/Smad1, Smad2,
Smad3, Smad5 and Smad8), inhibitory Smads (I-Smads/
Smad6 and Smad7) and the common-partner Smad (co-
Smad/Smad4). In osteoblasts BMPs preferably activate
Smad1/5/8 while TGFb1-3 activate Smad2/3 [12]. Upon
activation, Smads1/5/8 and Smads2/3 form complexes
with Smad4, which provides transcription factor activity,
regulating target gene expression in the nucleus [12]
including genes participating in feedback mechanisms of
the signaling pathway itself. Besides I-Smads, these genes
include Smad ubiquitination regulatory factor (Smurf)1
and Smurf2, Smad anchor for receptor activation (SARA),
BMP and activin receptor membrane bound inhibitor
(BAMBI), v-ski sarcoma viral oncogene homolog (Ski),
Ski-related novel protein N (SnoN), sclerostin and noggin.
While Smad6 specifically interferes with the Smad1/5/8
pathway, Smad7 is able to blunt both Smad1/5/8-mediated
as well as Smad2/3-mediated signal transduction. Mechan-
istically, I-Smads interact with TGFb family receptors and
Smad proteins in order to facilitate their ubiquitination
and degradation with the help of the E3 ubiquitin ligases
Smurf1 and Smurf2 [12]. SARA, known as a Smad cofac-
tor, directly interacts with Smad2 and favors its recruit-
ment to the TGFb receptor, thereby enhancing TGFb
signaling [12]. BAMBI has structural features of a decoy
receptor and inhibits TGFb/BMP signaling (receptor acti-
vation) by competing with the type I receptor for ligand
binding [12]. Ski and SnoN belong to the negative regula-
tors of Smad transcriptional function, antagonizing TGFb
signaling primarily through transcriptional modulation via
recruitment of nuclear transcriptional corepressor and his-
tone deacetylase (HDAC) [12]. Sclerostin regulates bone
mass by competing with BMP for receptor binding [13]. In
an earlier study, we demonstrated that TGFb1 inhibits
rhBMP-2 and rhBMP-7 signaling in primary human osteo-
blasts [14]. This finding is of particular interest, as patients
with various inflammatory reactions, for example, liver
fibrosis or cirrhosis, cardiac fibrosis, chronic renal failure
or fibrosis of other tissues, have constantly increased active
TGFb1 serum levels [15,16]. Distribution of the excessively
produced TGFb through the body via the bloodstream
may significantly influence the biological activity of
rhBMPs at fracture sites. Therefore, the aim of this study
was to identify the molecular details of the mechanism by
which rhTGFb1 inhibits rhBMP-2 and rhBMP-7 signaling
in primary human osteoblasts, in order to identify possible
therapeutic targets to resensitize patients with chronically
increased TGFb1 serum levels to BMP therapy.
Methods
Human recombinant (rh)TGFb1, rhBMP-2 and rhBMP-7
were from Peprotech (London, UK); cell culture medium
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and supplements were from PAA (Cölbe, Germany); pri-
mary and secondary antibodies were from Santa Cruz
Biotechnology (Heidelberg, Germany) and Cell Signaling
(Frankfurt am Main, Germany); chemicals were from
Sigma (Munich, Germany).
Isolation and culture of primary human osteoblasts
Osteoblasts were isolated from femur heads of patients
undergoing total hip replacement, in accordance with the
ethical code of the ‘Klinikum rechts der Isar’ (MRI, Tech-
nische Universität München, Germany) and the patients’
written consent. Briefly, cancellous bone was removed
mechanically from the femur head and washed three to
five times with Dulbecco’s phosphate buffered saline
(DPBS). After 1 h of collagenase digestion (DPBS, 0.07%
collagenase II; Biochrom AG, Berlin, Germany) at 37°C,
cancellous bone was washed with DPBS and released
osteoblast cells were transferred to cell culture flasks in
culture medium (minimal essential medium (MEM)/
Ham’s F12, 10% fetal calf serum (FCS), 2 mM L-gluta-
mine, 100 U/ml penicillin, 100 μg/ml streptomycin, 50 μM
L-ascorbate-2-phosphate, 50 μM b-glycerol phosphate) for
expansion. Medium was changed every 4 to 5 days.
Experiments were performed in passages 3 and 4, when a
pure population of osteoblasts was reached (negative for
CD14 and CD45 and positive for CD90 and CD105), as
determined by flow cytometry [14].
Transient cell infections and reporter gene assay
Cells were infected with Smad1/5/8 reporter adenovirus
particles (Ad5-BRE-Luc, provided by Dr O Korchynskyi
and Professor P ten Dijke (Leids Universitair Medisch
Centrum, Leiden, Netherlands) as described previously
[14]. Upon binding of phosphorylated Smad1/5/8/4 to the
plasmid, luciferase is expressed by the cells. Cell lysate pre-
paration and luciferase measurement were performed
according to the manufacturer’s instructions, using the
Steady-Glo Luciferase Assay System (Promega, Madison,
WI, USA) and normalized to total protein content. Infec-
tion efficiency was > 90%, as shown by fluorescent micro-
scopy of cells infected with Ad5-green fluorescent protein
(GFP) particles (24 h).
Conventional reverse transcription polymerase chain
reaction (RT-PCR)
Total cellular RNA was isolated using Trifast (Peqlab,
Erlangen, Germany) according to the manufacturer’s pro-
tocol. First-strand cDNA was synthesized from 1 μg total
RNA using the First Strand cDNA Synthesis Kit from Fer-
mentas (St. Leon-Rot, Germany). Primer information is
summarized in Table 1. Products, resolved by gel electro-
phoresis in a 1.8% (w/v) agarose gel, were visualized with
ethidium bromide. Densitometric analysis of signals was
performed using the Image J software (NIH, Bethesda,
MD, USA).
Western blot
Cells were lysed in ice-cold radioimmunoprecipitation
assay (RIPA) lysis buffer (50 mM Tris; 250 mM NaCl; 2%
Nonidet-P40; 2.5 mM ethylenediaminetetra-acetic acid
(EDTA); 0.1% SDS; 0.5% deoxycholate; complete mini pro-
tease inhibitor and phosphatase inhibitor according to the
manufacturer’s instructions; pH = 7.2). Protein concentra-
tion was determined by micro-Lowry process [17]. A total
of 30 μg protein was separated by SDS-PAGE and trans-
ferred to nitrocellulose membranes (Roth, Karlsruhe, Ger-
many). After overnight incubation with primary antibodies
(1:1,000 in Tris-buffered saline/Tween 20 (TBST)) at 4°C,
membranes were incubated with the corresponding horse-
radish peroxidase-labeled secondary antibodies for 2 h at
room temperature. Chemiluminescent signals were
detected on x-ray films.
HDAC activity measurement
HDAC activity was determined in living cells using the
SensoLyte™ HDAC Activity Fluorometric Assay Kit
(AnaSpec, Fremont, CA, USA).
Statistics
Results are expressed as mean ± SEM of at least three
independent experiments (N ≥ 3) measured as triplicates
or more (n ≥ 3). Data sets were compared by one-way
analysis of variance followed by Bonferroni’s multiple
comparison test (GraphPad Prism Software, El Camino
Real, CA, USA). P < 0.05 was taken as minimum level of
significance.
Results
rhTGFb1 blocks rhBMP-2-mediated and rhBMP-7-mediated
Smad1/5/8 signaling in human osteoblasts
Primary human osteoblasts (N = 4) were infected with
Ad5-BRE-Luc adenoviral particles (Smad1/5/8 reporter
construct) and stimulated for 24, 48, 72 and 96 h with 50
ng/ml of rhBMP-2 or rhBMP-7. Luciferase activity was
measured in cell lysates (n = 6). The highest luciferase sig-
nal was observed after 72 h (Figure 1A). Therefore, we
repeated the experiment (72 h stimulation with 50 ng/ml
rhBMP-2 or rhBMP-7) in the presence or absence of 5 ng/
ml rhTGFb1. Again, rhBMP-2 and rhBMP-7 induced
Smad1/5/8 signaling in primary human osteoblasts. How-
ever, addition of rhTGFb1 completely blocked rhBMP-2-
mediated and rhBMP-7-mediated Smad1/5/8 signaling
(Figure 1B). Stimulation with rhTGFb1 itself did not
induce Smad1/5/8 signaling in primary human osteoblasts
[14].
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Table 1 Summary of polymerase chain reaction (PCR) conditions
Gene GeneBank accession no. [NM_] Forward primer 5’-3’ Reverse primer 5’-3’ Tm (°C) Product length (bp)
Alk1 NM_000020.1 GCTCAGACACGACAACATCC ATTGCGGCTCTTGAAGTCG 60 256
Alk2 NM_001616.2 CTTGCATTGCTGACTTTGG CCAATTTCCTCCTCAAATGG 60 253
Alk3 NM_004329 CACTGCCCCCTGTTGTCATAG ATCCTGTTCCAAATCACGATTGT 58 179
Alk5 NM_004612.1 TGTTGGTACCCAAGGAAAGC AACATCGTCGAGCAATTTCC 60 287
Alk6 NM_001203 CTTTTGCGAAGTGCAGGAAAAT TGTTGACTGAGTCTTCTGGACAA 56 130
TGFbRII NM_3242.3 ATGCTGCTTCTCCAAAGTGC AGGTTGAACTCACGTTCTGC 57 258
Smad1 NM_005900.1 CAACGGAGTAACTGTGTCACC ATTCGCTGTGTCTTGGAACC 60 259
Smad2 NM_00100365 CAAACCAGGTCTCTTGATGG GAGGCGGAAGTTCTGTTAGG 60 259
Smad3 NM_005902.2 GGAGAAATGGTGCGAGAAGG GAAGGCGAACTCACACAGC 60 258
Smad4 NM_005359.3 TGAATCCATATCACTACGAAC CAGGCTGACTTGTGGAAG 60 294
Smad5 NM_005903.5 AACCTGAGCCACAAGAAC GGCTGGGAATTATCTTGACC 60 245
Smad6 NM_U59914 GGCAAACCCATAGAGACACAA GGTAGCCTCCGTTTCAGTGTA 56 123
Smad7 NM_005904.1 TTCGGACAACAAGAGTCAGC AAGCCTTGATGGAGAAACC 60 201
Smurf1 NM_020429.1 CAGCATCAAGATCCGTCTGA GCATAGATCCAAACGCTGGT 58 325
Smurf2 NM_022739.3 AGACTGGTGTGAGCACATGG CACTTGCTGTTGCTGTTGGT 58 239
SARA NM_007324.2 TGGTTTGCTGATGGGATCTT TTCCAACAGGACTTCCAACC 58 196
BAMBI NM_012342.2 GGATCGCCACTCCAGCTAC TGGTGTCCGTGAAAGCTGTA 58 603
Ski NM_003036.3 TCCGCGTGTACCACGAGTGC AGCAGGATGTAGGCCCGCCA 60 208
SnoN NM_005414.3 GCCACGAACTTTTCCTCAAA GCTGGGGTGTAAAAATGAATG 58 493
Noggin NM_005450.4 CAGCGACAACCTGCCCCTGG GATCTCGCTCGGCATGGCCC 56 249
Sclerostin NM_025237.2 CAGCTGCCGCGAGCTGCACT GCACTTGCACGAGGCCACCA 62 248
b-Actin NM_001101.3 CGACAACGGCTCCGGCATGT GCACAGTGTGGGTGACCCCG 64 461
Alk = activin receptor-like kinase; BAMBI = bone morphogenic protein and activin receptor membrane bound inhibitor; SARA = Smad anchor for receptor
activation; Ski = v-ski sarcoma viral oncogene homolog; Smurf = Smad ubiquitination regulatory factors; SnoN = Ski-related novel protein N; TGFbRII =
transforming growth factor b receptor II.
Figure 1 Recombinant human transforming growth factor b1 (rhTGFb1) blocks recombinant human bone morphogenic protein
(rhBMP)-2-mediated and rhBMP-7-mediated Smad1/5/8 signaling in primary human osteoblasts. (A) Primary human osteoblasts (N = 4)
infected with Ad5-BRE-Luc adenoviral particles (Smad1/5/8 reporter construct) were stimulated for 24, 48, 72 and 96 h with 50 ng/ml rhBMP-2 or
rhBMP-7. Luciferase activity was measured in cell lysates (n = 6). The single dose rhBMP-2 and rhBMP-7 induced Smad1/5/8 signaling with a
peak signal after 72 h. *P < 0.05; **P < 0.01; ***P < 0.001 as compared to untreated cells in the case of rhBMP-2. °°°P < 0.001 as compared to
untreated cells in the case of rhBMP-7. (B) Repetition of the experiment in the presence or absence of 5 ng/ml rhTGFb1 for 72 h. The addition of
rhTGFb1 (hatched bars) completely blocked rhBMP-2-mediated (light gray bars) and rhBMP-7-mediated (dark gray bars) Smad1/5/8 signaling. ***P
< 0.001 as compared to untreated cells. °P < 0.05; °°°P < 0.001 as compared to the corresponding rhBMP-2 and rhBMP-7 treated cells.
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rhTGFb1 reduces Smad1, Smad6, TGFbRs and BAMBI
expression but induces Smad7 and SnoN expression in
human osteoblasts
Primary human osteoblasts (N = 3) were treated with 50
ng/ml of rhBMP-2 or rhBMP-7 in the presence or absence
of 5 ng/ml rhTGFb1. After 72 h, mRNA was isolated for
expression analysis. RT-PCR experiments were performed
for the transcription factors Smad1-7, the receptors Alk1-
3, Alk5, Alk6 and TGFbRII as well as for the regulatory
elements Smurf1, Smurf2, SARA, BAMBI, Ski, SnoN, nog-
gin and sclerostin. b-Actin was used as housekeeping
gene. Densitometric analysis (n = 6) showed that mRNA
levels of Smad1, Smad6 and TGFb receptors I (Alk1) and
II were strongly downregulated upon stimulation with
rhTGFb1 (Figure 2A-D). Similarly, BAMBI showed a ten-
dency to be downregulated by rhTGFb1. At the contrary,
mRNA levels of the Smad7 and SnoN were significantly
upregulated by rhTGFb1 (Figure 2E, F). All the other
genes investigated were not significantly changed by
rhBMP-2, rhBMP-7 or rhTGFb1.
Protein levels of Smad1 and TGFbR were reduced,
whereas SnoN was increased by rhTGFb1 in human
osteoblasts
Primary human osteoblasts (N = 7) were treated with 50
ng/ml rhBMP-2 or rhBMP-7 in the presence or absence of
5 ng/ml rhTGFb1. After 72 h cells were lysed for western
blot analysis. Membranes were probed for Smad1/2, phos-
pho-Smad1/5/8, TGFbR and SnoN. Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) was used as loading
control (Figure 3A). Densitometric analysis (n = 6) con-
firmed reduced Smad1/5/8 phosphorylation (Figure 3B),
downregulation of Smad1 and TGFbR (Figure 3C, D) as
well as upregulation of SnoN (Figure 3E) by rhTGFb1 at
the protein level. Expression of Smad2 was not signifi-
cantly changed by the different treatments.
The BMP-2/BMP-7 antagonizing effect of rhTGFb1 in
primary human osteoblasts is mediated via induction of
HDAC activity
Treatment of primary human osteoblasts (N = 4, n = 3)
with 5 ng/ml rhTGFb1 for 72 h significantly induced
HDAC activity. Two subtoxic doses (100 μM and 200
μM) of the HDAC inhibitor valproic acid effectively
inhibited HDAC activity in our system (Figure 4A). In
order to investigate whether the BMP-2/BMP-7 antago-
nizing effect of rhTGFb1 is dependent on the increased
HDAC activity, we repeated the Smad1/5/8 reporter
assay in the presence or absence of the HDAC inhibitor.
Therefore, Ad5-BRE-Luc infected osteoblasts were coin-
cubated with 100/200 μM valproic acid and 50 ng/ml
rhBMP-2 or rhBMP-7 in the presence or absence of 5
ng/ml rhTGFb1. Valproic acid effectively countered the
BMP-2/BMP-7 antagonizing effect of rhTGFb1, as
measured by luciferase activity in cell lysates. Interest-
ingly, Smad1/5/8 signaling induced by rhBMP-2 and
rhBMP-7 in the setting of HDAC inhibition even
reached luciferase activity levels above those obtained by
rhBMP-2 and rhBMP-7 alone (Figure 4B).
Protein levels of Smad1, Smad2 and TGFbR were not
affected by valproic acid treatment
Primary human osteoblasts (N = 3) were treated with 50
ng/ml rhBMP-2 or rhBMP-7 or 100/200 μM valproic
acid in the presence or absence of 5 ng/ml rhTGFb1.
After 72 h cells were lysed for western blot analysis.
Membranes were probed for Smad1, Smad2, phospho-
Smad1/5/8, and TGFbR. GAPDH was used as loading
control (Figure 5A). Densitometric analysis (n = 6)
showed, besides reduced Smad1/5/8 phosphorylation and
downregulation of Smad1 and TGFbR by rhTGFb1, that
protein levels were not significantly affected by treatment
with valproic acid (Figure 5B-D).
Discussion
TGFb is secreted by bone cells. Therefore, bone repre-
sents one of the biggest reservoirs for all three TGFb iso-
forms (b1, b2 and b3) in the human body. In bone matrix,
the TGFb isoforms are present in their latent form,
which become activated upon need (for example, during
bone resorption by osteoclasts). The relevance of TGFb
for bone formation physiology is underlined by the find-
ing that TGFb1 knockout mice have a decreased tibia
length of about 30% and a reduced bone mineral content
[18]. Furthermore, local injection of TGFb1 under the
periosteum stimulates the formation of cartilage and
bone [19,20] and systemic application of TGFb2 leads to
a general increase in osteoblast activity [21]. In contrast,
transgenic mice with continuous overexpression of
TGFb2 in osteoblasts show a dramatic, age-dependent
loss of bone mass [22]. Along the same lines, transgenic
mice lacking functional TGFb signaling in osteoblasts
[23] or mice treated with the TGFb type I receptor kinase
inhibitor SD-208 [24] have increased trabecular bone
mass with tougher femurs and stiffer and stronger ver-
tebral bodies. Contrary to earlier findings, these data sug-
gest that continuous exposure to active TGFb might
harm bone physiology, as can be seen in patients suffer-
ing from chronic inflammation, whose active TGFb1
serum levels are often constantly increased. In an earlier
work, we showed that continuously elevated rhTGFb1
levels inhibit osteoblast function, for example, alkaline
phosphatase (AP) activity and formation of mineralized
matrix. One possible mechanism by which TGFb1 may
exert its inhibitory effect on osteoblast differentiation is
interfering with BMP signaling [14]. Therefore, the aim
of this study was to investigate possible regulatory
mechanisms by which rhTGFb1 inhibits rhBMP-2 and
Ehnert et al. BMC Medicine 2012, 10:101
http://www.biomedcentral.com/1741-7015/10/101
Page 5 of 11
Figure 2 Alterations in gene expression in primary human osteoblasts after treatment with recombinant human bone morphogenic
protein (rhBMP)-2, rhBMP-7 or recombinant human transforming growth factor b1 (rhTGFb1). Densitometric analysis (N = 3; n = 6) of
reverse transcription polymerase chain reaction (RT-PCR) signals from primary human osteoblasts treated with 50 ng/ml rhBMP-2 or rhBMP-7 ± 5
ng/ml rhTGFb1 for 72 h. Significant expression changes were observed in (A) R-Smad1, (B) I-Smad6, (C) activin receptor-like kinase (Alk)1, (D)
TGFb receptor II (TGFbRII), (E) Smad7 and (F) Ski-related novel protein N (SnoN). All other genes investigated were not significantly changed by
rhBMP-2, rhBMP-7 or rhTGFb1. *P < 0.05; **P < 0.01; ***P < 0.001 as compared to untreated cells.
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rhBMP-7 signaling in primary human osteoblasts. We
demonstrated that rhBMP-2 and rhBMP-7 induce
Smad1/5/8 signaling primary osteoblasts, isolated from
femoral heads of patients undergoing total hip replace-
ment. Upon a single stimulation with the cytokines, the
signaling reached its peak after 72 h. Coincubation with
only one-tenth of the amount of rhTGFb1 completely
abrogated the rhBMP-2-induced and rhBMP-7-induced
Smad1/5/8 signaling in these cells. The opposite is seen
in vivo in adult (rodent) kidney, where BMP-7 is
expressed and can, when administered exogenously,
reduce TGFb-driven renal fibrogenesis during experi-
mental chronic nephropathies [25]. Expression analysis
of the transcription factors (Smad1-5), receptors (Alk1-3,
Alk5, Alk6, TGFbRII) and regulatory factors (Smad6,
Smad7, Smurf1, Smurf2, SARA, BAMBI, Ski, SnoN, nog-
gin, sclerostin) involved in BMP or TGFb signaling,
revealed that rhTGFb1 downregulates the expression of
Smad1, Alk1 and TGFbRII, both at mRNA and at protein
level. This might explain the lack of Smad1/5/8 signaling
observed in osteoblasts treated with rhBMP-2 and
rhBMP-7 costimulated with rhTGFb1.
Interestingly, expression of Smad6 was also downregu-
lated by rhTGFb1, which should enhance Smad1/5/8 sig-
naling by reducing ubiquitination and degradation of
Smad1/5/8 and the corresponding receptors by the E3 ubi-
quitin ligases Smurf1 and Smurf2 [12], where expression
in osteoblasts was not affected in our setting. On the con-
trary, expression of the other inhibitors Smad6 and Smad7
was upregulated. As Smad7 binds to the activated recep-
tors in competition with Smad2/3 [12], and thus serves as
a negative feedback regulator for TGFb1-dependent
Smad2/3 signaling, its induction was not further investi-
gated at this point. Expression levels of the other tran-
scription factors and receptors were not significantly
altered in our experimental setup. Similarly, expression
levels of the majority of the investigated regulatory factors
investigated were not significantly altered in the presence
of rhBMP-2, rhBMP-7 or rhTGFb1, the only exceptions
being BAMBI and SnoN. The expression level of SnoN
was strongly increased in the presence of rhTGFb1. SnoN
interferes with TGFb signaling by interacting directly with
Smad3 [26]. Furthermore, SnoN is reported to antagonize
TGFb signaling on the transcriptional level via recruitment
Figure 3 Recombinant human transforming growth factor b1 (rhTGFb1) treatment alters protein levels of phospho-Smad1/5/8, Smad1,
TGFb receptor (TGFbR) and Ski-related novel protein N (SnoN) in primary human osteoblasts. (A) Representative western blot picture of
primary human osteoblasts treated with 50 ng/ml recombinant human bone morphogenic protein (rhBMP)-2 or rhBMP-7 ± 5 ng/ml rhTGFb1 for
72 h. Membranes were probed for phospho-Smad1/5/8, Smad1/2, TGFbR and SnoN. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was
used as loading control. Densitometric analysis (N = 6; n = 6) for (B) phospho-Smad1/5/8, (C) Smad1, (D) TGFbR and (E) SnoN. *P < 0.05; **P <
0.01; ***P < 0.001 as compared to untreated cells. °°P < 0.01; °°°P < 0.001.
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of HDACs [12]. Consequently, we demonstrated increased
general HDAC activity in rhTGFb1-treated human osteo-
blasts, which might be responsible for the observed
decreased expression levels of Smad1, Smad6, Alk1 and
TGFbRII. HDAC activity was effectively blocked by the
administration of two subtoxic doses (100 μM and 200
μM) of valproic acid. Blocking HDAC activity by valproic
acid was able to abolish the rhTGFb1-dependent inhibition
of rhBMP-2-induced and rhBMP-7-induced Smad1/5/8
signaling in our setup. However, valproic acid does have
severe side effects, thus detailed characterization of the
specific HDACs regulated by TGFb could identify a more
specific HDAC inhibitor for use in patients with less side
effects. Interestingly, BAMBI expression levels were
slightly downregulated in the presence of rhTGFb1 in our
system. This should enhance rhBMP-2 and rhBMP-7 sig-
naling as BAMBI, similar to noggin or sclerostin, has been
reported to negatively affect bone formation in vivo by
directly interfering with ligand-receptor binding, thus inhi-
biting both BMP and TGFb receptor binding [27,28]. In
contrast to that, SnoN affects both TGFb and BMP signal-
ing via transcriptional regulation. This points towards a
possible novel mechanism how rhBMP-2 and rhBMP-7
fracture therapies in patients could be optimized. Valproic
acid is already in clinical use as one of the most common
antiepileptic drugs with proposed off-label use as
Figure 4 Blocking increased histone deacetylase (HDAC) activity in recombinant human transforming growth factor b1 (rhTGFb1)-
treated primary human osteoblasts neutralizes the inhibitory effect of rhTGFb1 on recombinant human bone morphogenic protein
(rhBMP)-2 and rhBMP-7 signaling. (A) HDAC activity in primary human osteoblasts (N = 4, n = 3) treated with 5 ng/ml rhTGFb1 (gray bars) for
72 h. In order to inhibit HDAC activity lysates were coincubated with two subtoxic doses (100 μM and 200 μM) of valproic acid. Trichostatin A,
provided with the kit used, was used as inhibitor control. (B) Primary human osteoblasts (N = 4) infected with Ad5-BRE-Luc adenoviral particles
(Smad1/5/8 reporter construct) were stimulated with 50 ng/ml rhBMP-2 (light grey bars) or rhBMP-7 (dark gray bars) ± 5 ng/ml rhTGFb1
(hatched bars) and 100 μM or 200 μM HDAC inhibitor (valproic acid) for 72 h. Luciferase activity was measured in cell lysates. The single dose of
rhBMP-2 or rhBMP-7 induced Smad1/5/8 signaling, which was completely blocked by rhTGFb1. Blocking HDAC activity with valproic acid
abolished the rhTGFb1-dependent inhibition of rhBMP-2 and rhBMP-7 induced Smad1/5/8 signaling. **P < 0.01; ***P < 0.001.
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anticancer drug [29,30]. However, it still lacks evaluation
in vivo as valproic acid is reported to have severe side
effects, for example, embryotoxicity. By identification of
the specific HDACs regulated by TGFb, an alternative
HDAC inhibitor with fewer side effects could be chosen.
Furthermore, as this study focused on primary human
osteoblasts as the major target for BMP therapy, the
effects of the chosen HDAC inhibitor on bone resorption
by osteoclasts should be also investigated. The latter in
particularly is limiting for the present study set, since little
is known of how HDAC inhibitors may interact with
osteoclasts or with a corresponding coculture system.
Despite the overall positive results on the use of rhBMP-2
or rhBMP-7 on bone as an adjunct or as a replacement for
autograft in compromised patients [2-7], several adverse
events, for example, infections, hardware failure, pain,
donor site morbidity, heterotopic bone formation and
immunogenic reactions, have been reported nonetheless
[8,9]. In the present experiments addition of valproic acid
not only abolished the inhibitory effect of rhTGFb1 on
rhBMP-2 and rhBMP-7 signaling, but even increased
Smad1/5/8 signaling. This is supported by the findings of
Schroeder and Westendorf that show that application of
HDAC inhibitors, trichostatin A, sodium burtyrate, val-
proic acid and MS-275 favors osteoblasts maturation in
MC3T3-E1 cells by upregulation of RUNX2 [31]. Interest-
ingly, patients with epilepsy show an increased fracture
risk. Thus, it has be extensively studied how antiepileptic
drugs affect bone turnover; however, no correlation
between valproate medication and loss in bone mineral
density was observed [32,33]. This favors the use of this
drug for improving BMP therapy. However, it should be
further investigated in which way the drug should be
administered for improving BMP therapy. An oral applica-
tion may have advantages for the clinicians to treat
patients that already show BMP therapy failure without an
additional operation. However, oral administration of
valproate may hold the risk for more side effects from the
drug per se. This could be limited by a local application of
the drug in combination with the BMP itself. Also, to
further minimize possible adverse effects by the applied
drug it should be further clarified which HDACs are
involved in the observed gene regulation to possibly
choose a more selective inhibitor with fewer side effects.
Figure 5 Valproic acid treatment does not affect protein levels of phospho-Smad1/5/8, Smad1, Smad2 and transforming growth
factor b receptor (TGFbR) in primary human osteoblasts. (A) Representative western blot picture of primary human osteoblasts treated with
50 ng/ml recombinant human bone morphogenic protein (rhBMP)-2 or rhBMP-7 as well as 100/200 μM valproic acid ± 5 ng/ml rhTGFb1 for 72
h. Membranes were probed for Smad1, Smad2, phospho-Smad1/5/8 and TGFbR. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used
as loading control. Densitometric analysis (N = 3; n = 6) for (B) phospho-Smad1/5/8, (C) Smad1 and (D) TGFbR. *P < 0.05; **P < 0.01; ***P <
0.001 as compared to untreated cells. °°°P < 0.001.
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Conclusions
Based on our data a more general use of valproic acid as
an adjunct for rhBMP-2 or rhBMP-7 might be feasible in
order to generally increase the efficiency of rhBMPs in
vivo and thus, reduce therapeutic costs, making the ther-
apy available for a broader range of patients.
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